Urinary proteomic profiling for diagnostic bladder cancer biomarkers.
The ability to detect and monitor bladder cancer in noninvasively obtained urine samples is a major goal. While a number of protein biomarkers have been identified and commercially developed, none have greatly improved the accuracy of sample evaluation over invasive cystoscopy. The ongoing development of high-throughput proteomic profiling technologies will facilitate the identification of molecular signatures that are associated with bladder disease. The appropriate use of these approaches has the potential to provide efficient biomarkers for the early detection and monitoring of recurrent bladder cancer. Identification of disease-associated proteins will also advance our knowledge of tumor biology, which, in turn, will enable development of targeted therapeutics aimed at reducing morbidity from bladder cancer. In this article, we focus on the accumulating proteomic signatures of urine in health and disease, and discuss expected future developments in this field of research.
Goodison
Steve
S
MD Anderson Cancer Center - Orlando, Cancer Research Institute, 6900 Lake Nona Boulevard, Orlando, FL 32827, USA. goodison.steve@gmail.com
Rosser
Charles J
CJ
Urquidi
Virginia
V
D014408:Biomarkers, Tumor / Q000652:urine*; D006801:Humans; D011507:Proteinuria / Q000652:urine*; D040901:Proteomics; D001749:Urinary Bladder Neoplasms / Q000175:diagnosis* / Q000652:urine
D014408:Biomarkers, Tumor